Therapeutics company Titan Pharmaceuticals Inc (NASDAQ:TTNP) stated on Monday its net loss of USD9.3m (USD1.64 per common share) for the full year ended 31 December 2018.
This reflects a growth when compared with a higher net loss of USD14.3m (USD4.05 per common share) for 2017.
Total revenues of USD6.6m were generated for the full year ended 31 December 2018, arise over total revenues of USD0.2m in 2017.
R&D expenses of USD7.5m were recorded for the year ended 31 December 2018, a decline from R&D of USD9.6m in 2017.
The company added that the drop in R&D costs was primarily associated with decreases in external R&D expenses related to the support of ProNeura product development programmes, employee related expenses and other R&D expenses.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government